专利检索 cpc:"C12Y304/21098" 第 1 页

1.

发明授权
RNA-based delivery systems with levels of control 有权

公开(公告)号：US11946066B2

公开(公告)日：2024-04-02

申请号：US17935024

申请日：2022-09-23

申请人： California Institute of Technology

发明人： Xiaojing Gao , Lucy S. Chong , Michael B. Elowitz , Matthew S-M Kim

IPC分类号： C12N15/86 , C07K14/005 , C07K14/81 , C07K16/18 , C12N7/00 , C12N9/50 , C12N15/62

CPC分类号： C12N15/86 , C07K14/005 , C07K16/18 , C12N7/00 , C12N9/506 , C12N15/62 , C12Y304/21098 , C07K2317/569 , C07K2317/622 , C07K2319/30 , C07K2319/50 , C12N2740/11045 , C12N2760/20143 , C12N2810/6054 , C12N2820/002 , C12N2820/007

摘要： Disclosed herein include methods, compositions, and systems suitable for use in delivering a polynucleotide to a target cell of a subject in need thereof. In some embodiments, a viral vector comprises a polynucleotide encoding nucleoprotein (N), phosphoprotein (P), matrix protein (M), RNA-dependent RNA polymerase (L), and one or more transgenes. The viral vector can comprise one or more of a conditionally stable fusion protein, a protease fusion protein, a degron fusion protein, and/or a glycoprotein derived of another species than the viral vector polynucleotide to enable control of viral vector transduction and/or replication.

2.

发明申请
HCV PROTEASE INHIBITORS AND USES THEREOF 审中-公开

公开(公告)号：US20160326216A1

公开(公告)日：2016-11-10

申请号：US15222592

申请日：2016-07-28

申请人： Celgene Avilomics Research, Inc.

发明人： Deqiang Niu , Russell C. Petter , Lixin Qiao , Juswinder Singh

IPC分类号： C07K7/06 , C07K5/08 , C12N9/50 , A61K38/06 , A61K38/08 , C12N9/99 , C07K5/093 , A61K45/06

CPC分类号： C07K7/06 , A61K31/40 , A61K31/403 , A61K31/4439 , A61K31/4965 , A61K31/506 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/08 , A61K45/06 , C07D209/52 , C07D401/12 , C07D403/12 , C07K5/06165 , C07K5/0802 , C07K5/0804 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/0821 , C07K5/0827 , C07K5/1016 , C12N9/506 , C12N9/99 , C12Y304/21098

摘要： The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

3.

发明授权
Programmable protein circuits in living cells 有权

公开(公告)号：US11965191B2

公开(公告)日：2024-04-23

申请号：US17157880

申请日：2021-01-25

申请人： California Institute of Technology

发明人： Xiaojing Gao , Lucy S. Chong , Michael Elowitz , Mark William Budde , Matthew Sun-min Kim

IPC分类号： C12N9/50 , C12N9/06 , C12N9/96

CPC分类号： C12N9/506 , C12N9/003 , C12N9/96 , C12Y105/01003 , C12Y304/21098 , C12Y304/22044 , C07K2319/50

摘要： The present disclosure relates to systems, methods and compositions provided herein that include a compound protease. The compound protease can contain a protease domain, a cut site for another enzyme and an association domain. In some embodiments, the compound protease is part of a protein circuit.

4.

发明公开
RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL 审中-公开

公开(公告)号：US20230193317A1

公开(公告)日：2023-06-22

申请号：US17935024

申请日：2022-09-23

申请人： California Institute of Technology

发明人： Xiaojing Gao , Lucy S. Chong , Michael B. Elowitz , Matthew S-M Kim

IPC分类号： C12N15/86 , C12N15/62 , C07K16/18 , C07K14/005 , C12N9/50 , C12N7/00

CPC分类号： C12N15/86 , C12N15/62 , C07K16/18 , C07K14/005 , C12Y304/21098 , C12N9/506 , C12N7/00 , C12N2820/007 , C07K2317/622 , C07K2317/569 , C07K2319/50 , C07K2319/30 , C12N2760/20143 , C12N2820/002 , C12N2740/11045 , C12N2810/6054

摘要： Disclosed herein include methods, compositions, and systems suitable for use in delivering a polynucleotide to a target cell of a subject in need thereof. In some embodiments, a viral vector comprises a polynucleotide encoding nucleoprotein (N), phosphoprotein (P), matrix protein (M), RNA-dependent RNA polymerase (L), and one or more transgenes. The viral vector can comprise one or more of a conditionally stable fusion protein, a protease fusion protein, a degron fusion protein, and/or a glycoprotein derived of another species than the viral vector polynucleotide to enable control of viral vector transduction and/or replication.

5.

发明申请
HCV PROTEASE INHIBITORS AND USES THEREOF 有权

公开(公告)号：US20150175657A1

公开(公告)日：2015-06-25

申请号：US14639228

申请日：2015-03-05

申请人： Celgene Avilomics Research, Inc.

发明人： Deqiang Niu , Russell C. Petter , Lixin Qiao , Juswinder Signh

IPC分类号： C07K5/087 , A61K38/06 , C12N9/50 , A61K38/07 , C12N9/99 , A61K45/06 , C07K5/107

CPC分类号： C07K7/06 , A61K31/40 , A61K31/403 , A61K31/4439 , A61K31/4965 , A61K31/506 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/08 , A61K45/06 , C07D209/52 , C07D401/12 , C07D403/12 , C07K5/06165 , C07K5/0802 , C07K5/0804 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/0821 , C07K5/0827 , C07K5/1016 , C12N9/506 , C12N9/99 , C12Y304/21098

摘要： The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

6.

发明申请
DEGRON FUSION CONSTRUCTS AND METHODS FOR CONTROLLING PROTEIN PRODUCTION 审中-公开

公开(公告)号：US20180179509A1

公开(公告)日：2018-06-28

申请号：US15737712

申请日：2016-06-28

申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

发明人： Michael Z. LIN , Hokyung CHUNG , Conor JACOBS

IPC分类号： C12N9/50 , G01N33/68 , C12N15/86

CPC分类号： C12N9/506 , C07K2319/50 , C07K2319/95 , C12N9/48 , C12N15/86 , C12N2760/18421 , C12N2760/18432 , C12N2760/18443 , C12Q1/70 , C12Y304/21098 , G01N33/68

摘要： Engineered fusion proteins comprising a self-excising degron for controlling protein production are disclosed. In particular, the inventors have constructed fusion proteins comprising a degron connected to a protein of interest through a cleavable linker comprising a hepatitis C virus (HCV) protease site. The degron can be removed from the protein of interest by a czs-encoded HCV protease such that the protein of interest can be produced with minimal structural modification. Clinically available HCV protease inhibitors can be used to block protease cleavage such that the degron is retained after inhibitor addition on subsequently synthesized protein copies. The degron when attached causes rapid degradation of the linked protein. Such fusions of a degron to a protein of interest will be especially useful when control over protein production with minimal structural modification is desired.